AZD4547 is a selective inhibitor of fibroblast growth factor receptors (FGFRs), particularly FGFR1, FGFR2, and FGFR3. It is primarily investigated for its potential in cancer therapy, especially in tumors driven by FGFR signaling pathway abnormalities. This includes certain types of lung, breast, gastric, and bladder cancers where FGFR gene amplifications or mutations lead to uncontrolled cell proliferation.

The compound has shown activity in preclinical models by blocking tumor growth and inducing apoptosis in cancer cells dependent on FGFR signaling. It is used in research settings to understand FGFR-driven oncogenesis and as a candidate in clinical trials evaluating its efficacy alone or in combination with other anticancer agents. Its development highlights the role of targeted therapies in precision oncology, aiming to match treatment to the genetic profile of a patient’s tumor.